SG11201802470SA - Egfr kinase inhibitor and preparation method and use thereof - Google Patents
Egfr kinase inhibitor and preparation method and use thereofInfo
- Publication number
- SG11201802470SA SG11201802470SA SG11201802470SA SG11201802470SA SG11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- kinase inhibitor
- egfr kinase
- egfr
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510622837.4A CN106554347B (en) | 2015-09-25 | 2015-09-25 | EGFR kinase inhibitor and preparation method and application thereof |
PCT/CN2016/089679 WO2017049992A1 (en) | 2015-09-25 | 2016-07-11 | Egfr kinase inhibitor and preparation method and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201802470SA true SG11201802470SA (en) | 2018-04-27 |
Family
ID=58385839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802470SA SG11201802470SA (en) | 2015-09-25 | 2016-07-11 | Egfr kinase inhibitor and preparation method and use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US10710979B2 (en) |
EP (1) | EP3354647B1 (en) |
JP (1) | JP6752283B2 (en) |
KR (1) | KR20180096575A (en) |
CN (1) | CN106554347B (en) |
AU (1) | AU2016327857B2 (en) |
BR (1) | BR112018005795A2 (en) |
CA (1) | CA2999785C (en) |
RU (1) | RU2018115278A (en) |
SG (1) | SG11201802470SA (en) |
WO (1) | WO2017049992A1 (en) |
ZA (1) | ZA201802141B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI778943B (en) | 2015-10-01 | 2022-10-01 | 美商潛能醫療有限公司 | Anti-tigit antigen-binding proteins and methods of use thereof |
JOP20190203A1 (en) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110025224A (en) * | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | Heteroaryl compounds and uses thereof |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
TWI545115B (en) | 2010-11-01 | 2016-08-11 | 阿維拉製藥公司 | Heterocyclic compounds and uses thereof |
JP5957003B2 (en) * | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Mutant selective EGFR inhibitor and use thereof |
CN104583195B (en) * | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | Nitrogenous heteroaromatic ring derivative as tyrosine kinase inhibitor |
NO2718543T3 (en) * | 2014-02-04 | 2018-01-06 | ||
CN104860890B (en) * | 2015-04-29 | 2018-03-13 | 上海泓博智源医药股份有限公司 | T790M mutant egfs R inhibitor and its application in antineoplastic is prepared |
CN105461640B (en) | 2015-12-02 | 2017-11-21 | 芷威(上海)化学科技有限公司 | A kind of preparation method of tyrosine kinase inhibitor |
-
2015
- 2015-09-25 CN CN201510622837.4A patent/CN106554347B/en active Active
-
2016
- 2016-07-11 JP JP2018535217A patent/JP6752283B2/en not_active Expired - Fee Related
- 2016-07-11 US US15/763,156 patent/US10710979B2/en active Active
- 2016-07-11 KR KR1020187011753A patent/KR20180096575A/en not_active Application Discontinuation
- 2016-07-11 BR BR112018005795A patent/BR112018005795A2/en not_active Application Discontinuation
- 2016-07-11 RU RU2018115278A patent/RU2018115278A/en not_active Application Discontinuation
- 2016-07-11 WO PCT/CN2016/089679 patent/WO2017049992A1/en active Application Filing
- 2016-07-11 SG SG11201802470SA patent/SG11201802470SA/en unknown
- 2016-07-11 CA CA2999785A patent/CA2999785C/en active Active
- 2016-07-11 AU AU2016327857A patent/AU2016327857B2/en not_active Ceased
- 2016-07-11 EP EP16847874.1A patent/EP3354647B1/en active Active
-
2018
- 2018-04-03 ZA ZA2018/02141A patent/ZA201802141B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN106554347A (en) | 2017-04-05 |
CA2999785A1 (en) | 2017-03-30 |
EP3354647B1 (en) | 2022-08-24 |
JP6752283B2 (en) | 2020-09-09 |
WO2017049992A1 (en) | 2017-03-30 |
JP2018536698A (en) | 2018-12-13 |
AU2016327857B2 (en) | 2019-10-03 |
US20180346444A1 (en) | 2018-12-06 |
CA2999785C (en) | 2020-10-27 |
RU2018115278A3 (en) | 2019-10-28 |
US10710979B2 (en) | 2020-07-14 |
RU2018115278A (en) | 2019-10-28 |
BR112018005795A2 (en) | 2019-01-15 |
EP3354647A4 (en) | 2019-04-03 |
KR20180096575A (en) | 2018-08-29 |
CN106554347B (en) | 2020-10-30 |
AU2016327857A1 (en) | 2018-04-26 |
ZA201802141B (en) | 2019-01-30 |
EP3354647A1 (en) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279258B (en) | Tyrosine kinase inhibitors | |
HK1252693A1 (en) | Inhibitors of egfr and methods of use thereof | |
HK1248231A1 (en) | Substituted quinazoline compounds and methods of use thereof | |
ZA201701465B (en) | Egfr inhibitor, and preparation and application thereof | |
HK1246286A1 (en) | Lrrk2 inhibitors and methods of making and using the same | |
IL259711A (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
PL3277681T3 (en) | Imidazolonylquinolines and their use as atm kinase inhibitors | |
HK1249497A1 (en) | Ebna1 inhibitors and methods using same | |
ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
GB201514760D0 (en) | Compounds and method of use | |
ZA201802141B (en) | Egfr kinase inhibitor and preparation method and use thereof | |
HK1250028A1 (en) | 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors | |
HK1250926A1 (en) | Inhibitors and their uses | |
ZA201903845B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201519381D0 (en) | Kinase inhibitors | |
GB201519382D0 (en) | Kinase inhibitors | |
GB201505975D0 (en) | Inhibitors and their uses | |
GB201505971D0 (en) | Inhibitors and their uses | |
GB201502247D0 (en) | Formulation and method |